Looking for Abemaciclib found 7 matches
|
Open monograph to display formulary status |
BNF Category |
|
Abemaciclib
(Verzenios®)
|
Malignant disease and immunosuppression - Breast cancer - 08.03.04.01
|
|
Links Link to Drug Section Link to document |
MHRA Drug Safety Update (June 2021): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases (08.03.04.01)
|
MHRA Drug Safety Update (June 2021): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases (08.03.04.01)
|
MHRA Drug Safety Update (June 2021): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases (08.03.04.01)
|
NICE TA 563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (08.03.04.01)
|
NICE TA725: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (08.03.04.01)
|
NICE TA810: Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence (08.03.04.01)
|
|
|